Bhumika Shah | Psychiatrist.com

Commentary

Opioid Use Disorder Treatment and Interaction With COVID-19 Medication

In this commentary, the authors discuss the potential interactions of opioid use disorder treatments with novel COVID-19 medications.

Commentary

Potential Interactions of Remdesivir With Psychotropics

The FDA has approved remdesivir for severe COVID-19 in children and adults. This commentary reviews potential interactions of remdesivir with psychotropic medications.

Commentary

Interactions of Ritonavir/Lopinavir With Psychiatric Medications: A COVID-19 Perspective

In this commentary, the authors discuss the potential interactions of ritonavir/lopinavir with psychiatric medications in the context of COVID-19.

Letter to the Editor

Interactions With IL-6 Inhibitors and Agents for Opioid Use: Drs Mansuri and Colleagues Reply

In this letter to the editor, the authors reply to Kow and Hasan.

Impact of Paternal Depression on Children

Systematic Review

Impact of Paternal Depression on Children

An association exists between paternal mental health and depressive symptoms and neurodevelopmental disorders in infants and children.

Drug Interactions Between Psychotropic Medications and Mpox Treatment

Letter to the Editor

Drug Interactions Between Psychotropic Medications and Mpox Treatment

The authors review pharmacologic interactions of Mpox treatments with psychotropic medications and antidepressants, antipsychotics, mood stabilizers, and sedatives.

Intravenous Ketamine vs Intranasal Esketamine for TRD

Letter to the Editor

Intravenous Ketamine vs Intranasal Esketamine for TRD

Dr Mansuri and colleagues compare the pros and cons of IV ketamine and intranasal esketamine for treatment-resistant depression.